RxDoctor Payments Data

Rajesh Patel, MD

Internal Medicine · Media, PANPI 1265492763

Payments from drug & device makers

$50,576in general payments, 2019–2025

Across 675 payments — averaging $74.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$21K
  • Boehringer Ingelheim$9K
  • AstraZeneca$8K
  • Intuitive Surgical$3K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Insmed, Inc.$1K
  • plus $7K from 34 others

What the payments were for

  • Speaking & faculty fees$31,75363%
  • Travel & lodging$3,8288%
  • Food & beverage$14,54629%
  • Education$4501%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,576 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$502,263
Medicare patients
1,571
Services billed
6,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter564$667,700
OpsumitMacitentan16$309,531
Breo ElliptaFluticasone/Vilanterol236$167,824
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr120$84,360
Breztri AerosphereBudesonide/Glycopyr/Formoterol81$84,049
Spiriva RespimatTiotropium Bromide76$61,163
Pirfenidone23$48,807
SymbicortBudesonide/Formoterol Fumarate88$40,521
EliquisApixaban53$36,191
Fluticasone-SalmeterolFluticasone Propion/Salmeterol186$28,242
Incruse ElliptaUmeclidinium Bromide51$27,597
Bevespi AerosphereGlycopyrrolate/Formoterol Fum35$26,126
XareltoRivaroxaban22$15,416
Albuterol Sulfate HfaAlbuterol Sulfate328$9,158
JardianceEmpagliflozin25$9,041

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$20,598$947,482971 claims
Actelion Pharmaceuticals US, Inc.Opsumit$1,335$309,53116 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$8,498$150,697204 claims
Boehringer IngelheimSpiriva Respimat, Jardiance$9,127$70,204101 claims
Lilly USA, LLCOlanzapine$40$58414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Media

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →